The Bio21 Institute's 2017 Annual Report Is Available to Download

Total Page:16

File Type:pdf, Size:1020Kb

The Bio21 Institute's 2017 Annual Report Is Available to Download Annual Report 2017 The Bio21 Molecular Science and Director Associate Director – Platform Biotechnology Institute Professor Michael W. Parker Infrastructure University of Melbourne DPhil (Oxon) FAA FAHMS Professor Malcolm McConville 30 Flemington Road Deputy Director Associate Director – Commercialisation Parkville Victoria 3010 Professor Frances Separovic Professor Spencer Williams Telephone: (03) 8344 2220 PhD FAA www.bio21.unimelb.edu.au Associate Director – Engagement @Bio21Institute Scientific Research Manager Associate Professor Sally Gras @Bio21Institute Dr David Keizer Produced by the Bio21 Molecular Science and Biotechnology Communications and Engagement team b Bio21 Institute Annual Report 2017 Contents Our Mission 02 Our Vision 02 About the Institute 03 Director’s Message 04 Bio21 Leadership 06 Deputy Director Frances Separovic 06 Associate Directors Appointed 08 Associate Director Engagement – Associate Professor Sally Gras 08 Associate Director Commercialisation – Professor Spencer Williams 09 Associate Director Platform Infrastructure – Professor Malcolm McConville 09 New Group Leaders Welcomed 10 Impacts of Research 12 Enabling Platform Technologies 16 Scientific Research Manager’s Message 16 Industry Engagement and Commercialisation 18 External Relations, Communications and Engagement 20 Bio21 Visiting Delegations 20 Public and School Engagement 22 Bio21 Institute Internal Community Events and Engagement 26 Bio21 Hosted Events 27 Bio21 Graduate Researchers and Postdocs 29 Bio21 Institute Members Honoured 31 Grant Successes 34 Governance 38 Occupational Health and Safety Statement 39 Bio21 People 40 Institute in Numbers 42 Steering Committee 43 Papers Published 48 Bio21 Institute Annual Report 2017 1 Our Mission The Bio21 Institute seeks to improve human health and the environment through innovation in molecular life sciences and biotechnology, driven by collaborative research and dynamic interactions with industry. Our Vision Research Excellence: Shared resources: Industry Science Education To be leaders in To provide Core engagement and for secondary world-class Platform Technology Innovation: schools through the multidisciplinary Facilities to industry To nurture Australia’s partnership with the molecular science and academic biotechnology Elizabeth Blackburn research and research researchers sector Science School training 2 Bio21 Institute Annual Report 2017 About the Institute The University of Melbourne’s $140 million core research and development facility, Bio21 Molecular Science and Biotechnology Institute (Bio21 Institute), is a multidisciplinary molecular science research centre specialising in medical, agricultural and environmental biotechnology. Accommodating up to 600 academic and industry research scientists, the Bio21 Institute is one of the largest biotechnology research centres in Australia. The Bio21 Institute seeks to improve medical and other biomedical areas human health and the environment of biotechnology, are fundamental to through innovation in molecular science translating biological discoveries into biotechnology and related areas, driven biotechnology outcomes. The Institute by collaborative research and dynamic also embraces commercialisation as a interactions with industry. facilitator for scientific advancement, skills development and economic The commitment to establish the Bio21 outcomes. The Institute’s commitment Institute was the University of Melbourne’s to intellectual property protection, original contribution to the Bio21 Cluster technology transfer and business project, now known as Biomedical incubation are key drivers of this Research Victoria. innovation. Established in 2002, the Bio21 Institute The Bio21 Institute now attracts was officially launched on 8 June 2005 outstanding scientists and technicians by Victorian Premier Mr Steve Bracks, looking to use the purpose-built joined by University of Melbourne laboratories and state-of-the-art core Vice-Chancellor Professor Glyn Davis, platform technology facilities which Innovation Minister Mr John Brumby are accessible to these diverse scientific and Health Minister Ms Bronwyn Pike. and industry communities investigating A home of research and discovery various research themes. Included in this community are the start-up The Bio21 Institute was built on the companies supported through business premise that multidisciplinary ventures incubation and entrepreneurship skills between life sciences, physical sciences development, as well as students and and engineering disciplines, including early-career researchers. harnessing genomics knowledge in Bio21 Institute Annual Report 2017 3 Bio21 Welcomes Michael Parker as new director Professor Michael Parker formally took over from Professor Malcolm McConville as Director of Bio21 Molecular Science and Biotechnology Institute on 6 March 2017. As one of Australia’s leading protein structural biologists, Michael is exceptionally well placed to develop the strategic directions of the Institute and further promote the vibrant, multidisciplinary culture that has been established here. Michael’s research group moved into Bio21 Institute from the St Vincent’s Institute for Medical Research in a staged process during 2017. Director’s Message In March 2017 I took up my post as With 9 nuclear magnetic resonance Also, there are numerous examples within Director of the Bio21 Molecular Science spectrometers; 22 mass spectrometers and the Institute of collaboration that has and Biotechnology Institute. It is a great a high-end Advanced Microscopy facility led to truly innovative commercialisation honour to lead the Institute into an that is home to two new Cryo-electron successes, such as: Spencer William’s exciting future, located in one of the microscopes, Bio21 is uniquely positioned success with Fibrotech and Paul Donnelly’s great bioscience precincts in the world. with large, state-of-the-art technology to commercialisation of radiopharmaceuticals delve deeply into the structure and nature through Clarity Pharmaceuticals; Barnham As I step into this role, it is an opportunity of molecules, from small molecules, to and Donnelly labs commercialisation and to think about what kind of institute we peptides, proteins, nucleic acids and viruses. licencing of a motor neurone disease drug are, what we do and where we’re going. with Collaborative Medicinal Development Bio21 is not the ‘cancer’ centre, the ‘brain’, In the labs of the Bio21 Institute, true Pty Ltd (CMD); and collaborative work ‘infectious diseases’ or ‘sustainability’ innovation occurs. Bio21 is a scientific between Takeda Pharmaceuticals and institute; yet individual groups do success story and this was reflected the Tilley lab to show that proteasome- conduct research in all these fields. From in a Nature survey of leading research inhibiting cancer drugs can be repurposed understanding how malaria invades the institutions in Australia, where the to be effective against malaria. These body, to what makes mozzarella cheese Bio21 Institute figured prominently. great stories highlight the biotechnology stretchy, or how organisms can adapt to One strategy that has served many of us aspirations of Bio21. climate change – the common denominator well is to truly seek to work collaboratively is the molecular science approach we The Bio21 Institute was built with with our colleagues within and across all use to seek knowledge and solutions collaboration in mind. The architects disciplines, in academia and industry. to problems in health and disease, built bridges across the atrium with Recent successes that illustrate this are environment and agriculture and more break-out spaces to meet and chat. the ARC Linkage grants awarded to the generally the biological sciences. We The Institute is home to groups across Gleeson/Mintern labs with CSL; Wille lab are the ‘molecular sciences’ institute! the three faculties (Science, Medicine with Incitec Pivot Ltd, and the successful Dentistry and Health Sciences and the grant for the ARC Centre of Excellence in Melbourne School of Engineering). Excition Science (under the ARC Linkage scheme) led by Professor Paul Mulvaney. 4 Bio21 Institute Annual Report 2017 Our community also includes industry So, as Director of the Bio21 Molecular Michael W. Parker tenants CSL Ltd, Prana Biotech Ltd, Science and Biotechnology Institute, DPhil (Oxon) FAA FAHMS Circa Group and research groups from I endeavour to carry on the powerful Director, Bio21 Molecular Science and The Women’s Hospital and the Murdoch founding vision of the Institute which is Biotechnology Institute (Bio21 Institute) Children’s Research Institute. inherent in its name: a molecular science Professor, Department of Biochemistry and and biotechnology institute. A community Molecular Biology l University of Melbourne In the course of 2017, we saw the Stage of brilliant scientists, equipped with the NHMRC Senior Principal Research Fellow 2B building arise from its foundations. most cutting-edge instrumentation, Head of Structural Biology It is founded on collaboration between working together to improve human ACRF Rational Drug Discovery Centre CSL and the University of Melbourne and health and the environment through St. Vincent’s Institute of Medical Research will house CSL research groups as well as innovation in biotechnology and molecular groups from the University of Melbourne. sciences, driven by multidisciplinary We particularly thank Malcolm McConville, research and dynamic interactions previous Director and currently Associate with
Recommended publications
  • The University News, Vol. 5, No. 8, May 31, 1979
    VOL5N08 MAY 311979 Newsletter for I( The University of Newcastle New Oval Mater ial isi ng Enrolments Enrolment oJ students as at . April 30 totalled 4364 compared with 4429 in 1978. This rep­ resents an annual rate of decrease of 1% compared with 4% for 1977-78. The enrolment for higher degrees increased this year from 391 to 403 - a gain of 3%. There has been a 2% fall in the enrolment in other than higher degrees, now 3961 as against 4038 in 1978. Of the total enrolment 55% is full-time and 45% part-time. This compares wit~ 58% and 42% respectively in 1978. In terms of students the full-time enrol­ ment is 2392 and the part-time 1937. The male student numbers are 2735 or 63% of the total, and the female enrolment 1629. A combination of favourable When construction commenced earl­ or 37%. In 1978. 64% was male growing conditions and fertiliz­ ier this year sufficient finance and 36% female. ation has allowed rapid progress was available to complete only half of the project. Now it has The number of students from to be made with work on NO.3 overseas has continued to fall Oval. The Electricity Commission been decided to complete the from 188 in 1977, 160 in 1978 of New South Wales and the entire oval in the very near to 145 in 1979. University are jointly construct­ future. tng the playing area, which The University will have the use The greater number of our over­ covers almost the same area as of the oval for an initial period seas students came from: NO.1 Oval.
    [Show full text]
  • Seizure Dynamics
    Balson et al. BMC Neuroscience 2014, 15(Suppl 1):P152 http://www.biomedcentral.com/1471-2202/15/S1/P152 POSTERPRESENTATION Open Access Seizure dynamics: a computational model based approach demonstrating variability in seizure mechanisms Richard S Balson1,2,3,4*, Dean R Freestone1,2,3, Mark J Cook2,3, Anthony N Burkitt1,2,4, David B Grayden1,2,4 From The Twenty Third Annual Computational Neuroscience Meeting: CNS*2014 Québec City, Canada. 26-31 July 2014 Epilepsy is a neurological disorder that affects approxi- animals, based upon recorded LFP 150 seconds prior to mately 1% of the world’s population. At present, the and post seizure, as well as during the seizure. The esti- underlying mechanisms involved in seizure generation mation results show that, for three of the four animals, and termination are not fully understood. A computa- the mechanisms involved in their seizures are similar. tional model-based approach to provide further insights For the fourth animal, the estimated physiology prior to, into physiological changes occurring in the brain prior during, and post seizure vary drastically. When compar- to, during, and post seizure is presented. We demon- ing the physiological dynamics between animals, we strate that an unscented Kalman filter [1] can be used found that the estimation results predicted that there to fit physiological parameters of a neural mass model are different mechanisms involved in seizure initiation, [2] to recorded EEG. This technique elucidates physiolo- evolution, and termination in each animal. The common gical changes in recorded EEG that cannot be deter- element in all the results, except for a single estimated mined with standard EEG analysis methods.
    [Show full text]
  • Low Resolution
    Australian Biochemist The Magazine of the Australian Society for Biochemistry and Molecular Biology Inc. August 2019, Volume 50, Number 2 VOLISSN 50 NO 2 AUGUST 1443-0193 2019 AUSTRALIAN BIOCHEMIST PAGE 1 Be inspired during the 3- da y progra m including a fa nta stic lineup of industry lea ding interna tiona l plena ry spea kers, a nd hea r from our society specia lty lectures, be enga ged with poster presenta tions a nd lea rn a t the E/MCR mini- symposium. For more informa tion on our spea kers, progra m a nd to register, visit our website www.a sbmb2019.com.a u REGISTER NOW! PAGE 2 AUSTRALIAN BIOCHEMIST VOL 50 NO 2 AUGUST 2019 Table of Contents 4 Editorial Committee 5 Editorial 7 Publications with Impact Distinct Mechanisms Govern Recognition of Viral and Host Ligands by an Innate Immune Receptor Buying Time for Contractile Signaling Genetic Stutters, Gut Feelings and Neurodegenerative Disease 11 Off the Beaten Track Why it Sometimes Pays to Work for Money 14 ASBMB Education Feature Glycogen Builder: the Game Making a Drama Out of Biochemistry From the Whiteboard to the Conference: Scaffolding Conference-style Poster Presentations 18 SDS Page The Importance of Blue Sky Research 19 Competition: Unscramble 20 ASBMB 2019 International Plenary Speaker Profiles 22 ASBMB 2019 Symposium Speakers 23 Melbourne Protein Group: an ASBMB Special Interest Group 24 ASBMB Shimadzu Education Award Report 26 Intellectual Property Patenting Inventions in the Microbiome Space 29 Queen’s Birthday Honours for ASBMB Members 31 ASBMB Awards 2020 33 Election of Council 2020 33 Annual General Meeting of ASBMB 34 New ASBMB Members 35 Forthcoming Meetings 36 Our Sustaining Members 41 ASBMB Council 42 Directory Front Cover Bachelor of Biomedicine students from the University of Melbourne participating in an acting skills workshop with Rinske Ginsberg, VCA Theatre, as part of the Performing Sciences program, where students devise short performances embodying biochemical concepts.
    [Show full text]
  • Menzies School of Health Research
    MENZIES SCHOOL OF HEALTH RESEARCH 2020-21 Pre-Budget Submission September 2020 Contact: Professor Alan Cass Director, Menzies School of Health Research Ph: 08 8946 8600 Email: [email protected] Web: www.menzies.edu.au ABN: 70 413 542 847 Menzies School of Health Research (Menzies) is pleased to put forward its 2020-21 Pre-Budget submission. 1. Summary of recommendations The medical and health research sector has an important role in supporting economic growth, job creation and attracting investment to Australia. This role has been further emphasised in key policy statements from both the Northern Territory and Commonwealth Governments to ensure the future prosperity of northern Australia. For example, medical and health research is a stated economic priority in the Northern Territory Economic Development Framework and its Economic Reconstruction Priorities, as well as being highlighted as a strategic priority in the Commonwealth’s White Paper on Developing Northern Australia. Directly related to supporting medical and health research in northern Australia, this pre-budget submission requests that the Commonwealth provide $5m to support a four (4) year extension to the Northern Australia Tropical Disease Collaborative Research Program (NATDCRP), administered by Menzies School of Health Research in collaboration with seven (7) of Australia’s leading health research organisations – James Cook University, Telethon Kids Institute, Burnet Institute, The University of Sydney, the South Australian Health and Medical Research Institute, Doherty Institute and QIMR Berghofer Medical Research Institute. The NATDCRP – now referred to as the HOT North Program - was announced as a $6.8m budget measure by the Minister for Trade and Investment, the Hon Andrew Robb on 10 May 2015.
    [Show full text]
  • Melbourne Health Annual Report 2007/08
    Melbourne Health Annual Report 2007/08 1BTTJPOGPS $BSJOH"DIJFWJOH UIF&YUSBPSEJOBSZ PROFILE Prof Graham Brown There was none more deserving of the 2007 Melbourne Health Chairman’s Award than Prof Graham Brown. Prof Brown, an acclaimed infectious diseases physician, researcher and teacher, is passionate about public health and is highly regarded by colleagues for his outstanding leadership, intellect and ethical standards. Prof Brown this year took up the role of Foundation Director of the Nossal Institute for Global Health and Foundation Chair in Global Health at the University of Melbourne. Prof Brown’s association with Melbourne Health began as a medical student at RMH, then as a resident, medical registrar, consultant and ultimately, as the James Stewart Professor of Medicine. In 1996, he established the hospital’s renowned Victorian Infectious Diseases Service, taking responsibility for the many services transferred from the former Fairfi eld Infectious Diseases Hospital. “It was almost by chance that I ended up in Medical School, and incredible good fortune to be trained in the environment of RMH that valued academic- based medicine with strong links to Melbourne University. The mentorship, the collegiality, the pursuit of excellence, the challenging students, the superb nursing and allied health staff, and above all, the concern and care for every patient, set very high standards and a benchmark for my career in medicine.” CONTENT 43 Financial Statements 44 Operating Statement 45 Balance Sheet Contents 46 Cash Flow Statement 2 Chairman’s
    [Show full text]
  • Improving Outcomes of Deep Brain Stimulation for Essential Tremor with Motion Tracking and Speech Analysis
    IETF Grant Proposal: 27 February 2015 Improving Outcomes of Deep Brain Stimulation for Essential Tremor with Motion Tracking and Speech Analysis Brief Summary Deep Brain Stimulation (DBS) is a common form of treatment for medically refractory essential tremor (ET). DBS consists of one or two small electrode arrays that are placed in specific brain targets by a trained neurosurgeon. Controlled electrical pulses are then sent to these electrodes by a neuro- stimulator to modify brain activity and provide therapeutic benefit. The characteristics (duration, amplitude, and frequency) of these pulses must be set to minimize tremor, yet prevent unwanted side- effects such as speech difficulties. Usually, these parameters are set by a neurologist based on their observation of tremor and side-effect. In general, the ventral intermediate nucleus (VIM) of the brain is considered the most appropriate target for stimulation. Recently, however, the posterior subthalamic area (PSA) was also discovered to be an effective stimulation target. Since this discovery, much debate has ensued regarding which is the better target in terms of tremor and side-effect reduction. For each target, the stimulation level must also be considered due to influence on implant battery life. In this study we aim to determine which of the two targets provides the best outcome to the patient using novel methods to quantify tremor and side- effect. The majority of clinical assessments of ET rely on clinical scores based on observation. These are subjective measures influenced by the clinician’s opinion and experience. Unfortunately, the accuracy and sensitivity of such measures can be inadequate. To improve assessment of ET, we have developed our own method of tremor measurement based on electronic motion tracking.
    [Show full text]
  • Pfcerli1 Is a Conserved Rhoptry Associated Protein Essential for Plasmodium Falciparum Merozoite Invasion of Erythrocytes
    ARTICLE https://doi.org/10.1038/s41467-020-15127-w OPEN PfCERLI1 is a conserved rhoptry associated protein essential for Plasmodium falciparum merozoite invasion of erythrocytes Benjamin Liffner 1,8, Sonja Frölich 1,8, Gary K. Heinemann2, Boyin Liu3, Stuart A. Ralph 3, ✉ Matthew W.A. Dixon 3, Tim-Wolf Gilberger4,5,6 & Danny W. Wilson 1,7 1234567890():,; The disease-causing blood-stage of the Plasmodium falciparum lifecycle begins with invasion of human erythrocytes by merozoites. Many vaccine candidates with key roles in binding to the erythrocyte surface and entry are secreted from the large bulb-like rhoptry organelles at the apical tip of the merozoite. Here we identify an essential role for the conserved protein P. falciparum Cytosolically Exposed Rhoptry Leaflet Interacting protein 1 (PfCERLI1) in rhoptry function. We show that PfCERLI1 localises to the cytosolic face of the rhoptry bulb membrane and knockdown of PfCERLI1 inhibits merozoite invasion. While schizogony and merozoite organelle biogenesis appear normal, biochemical techniques and semi-quantitative super- resolution microscopy show that PfCERLI1 knockdown prevents secretion of key rhoptry antigens that coordinate merozoite invasion. PfCERLI1 is a rhoptry associated protein iden- tified to have a direct role in function of this essential merozoite invasion organelle, which has broader implications for understanding apicomplexan invasion biology. 1 Research Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Adelaide, SA 5005, Australia. 2 Experimental Therapeutics Laboratory, School of Pharmacy and Medical Sciences, University of South Australia Cancer Research Institute, Adelaide, SA 5005, Australia. 3 Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC 3010, Australia.
    [Show full text]
  • Melbourne Biomedical Precinct Studley Rd to an Exceptional Network Economic and Investment Growth Swinburne University of of Skilled Workers, Quality for the State
    The Royal Children’s Hospital + The Murdoch Children’s Research Institute The Royal Women’s Hospital Darwin Walter & Eliza Hall Institute Monash Institute of Pharmaceutical NT Science, Monash University + CSIRO QLD Royal Melbourne Hospital WA Brisbane C Florey Institute SA e m ete ry Rd The University of Melbourne NSW Perth Sydney A Precinct approach Victorian Comprehensive Cancer Centre Adelaide Royal Pde Canberra + Peter MacCallum Cancer Centre The Doherty Institute to collaboration Flemington Rd Elgin St St Vincent’s Hospital Melbourne Hobart Melbourne, Grattan St Swanston St Australia and innovation Arden St Curzon St Elizabeth St Lygon St La Trobe University Queensberry St d R g r e b Burgundy St Rathdowne St l Chetwynd St Victoria St e > id e Melbourne Brain Centre H r Peel St e Austin Health p Plan Melbourne, Victoria’s key metropolitan Franklin St p Melbourne has biomedical La Trobe St U Austin Hospital planning strategy, highlights the precincts Banksia St capabilities unparalleled in around Melbourne, Monash, Deakin, Olivia Newton-John Australia and amongst the and La Trobe universities as clusters CSL Cancer Wellness & world’s best. We are home which offer significant opportunities (Poplar Road) Research Centre for innovation as well as employment, Melbourne Biomedical Precinct Studley Rd to an exceptional network economic and investment growth Swinburne University of of skilled workers, quality for the state. Technology education providers, leading The Melbourne Biomedical Precinct Deakin University St Kilda Rd research institutes and a Partners are largely collocated to the Princes Hwy Commercial Rd Burwood & Geelong Campuses sophisticated health system. north of Melbourne’s CBD close to Monash University, Australia’s highest ranking university, Clayton � Caulfield There is a growing body of evidence the University of Melbourne.
    [Show full text]
  • 2010-2011 Annual Report
    Annual Report 2010-2011 Mastery of disease through discovery | www.wehi.edu.au Contents 1 About the institute 3 Director’s and Chairman’s report 5 Discovery 8 Cancer and Haematology 10 Stem Cells and Cancer 12 Molecular Genetics of Cancer 14 Chemical Biology 16 Molecular Medicine 18 Structural Biology 20 Bioinformatics 22 Infection and Immunity 24 Immunology The Walter and Eliza Hall Institute 26 Autoimmunity and Transplantation of Medical Research 28 Cell Signalling and Cell Death 1G Royal Parade 30 Inflammation Parkville Victoria 3052 Australia Telephone: (+61 3) 9345 2555 32 Molecular Immunology Facsimile: (+61 3) 9347 0852 34 Publications WEHI Biotechnology Centre 36 Awards 4 Research Avenue 37 Translation La Trobe R&D Park Bundoora Victoria 3086 Australia Translating our research 38 Telephone: (+61 3) 9345 2200 40 Developing our research Facsimile: (+61 3) 9345 2211 42 Patents www.wehi.edu.au www.facebook.com/WEHIresearch 43 Education www.twitter.com/WEHI_research 46 2010-11 graduates ABN 12 004 251 423 47 Seminars Acknowledgements 48 Institute awards Produced by the institute’s Community Relations department 49 Engagement Managing editor: Penny Fannin Editor: Liz Williams 51 Strategic partners Writers: Liz Williams, Vanessa Solomon and Julie Tester 52 Scientific and medical community Design and production: Simon Taplin Photography: Czesia Markiewicz and Cameron Wells 54 Public engagement 57 Engagement with schools Cover image 58 Donor and bequestor engagement Art in Science finalist 2010 Vessel webs 59 Sustainability Dr Leigh Coultas, Cancer and Haematology division 60 The Board This image shows the delicate intricacy in the developing eye of a transient population of web-like blood vessels.
    [Show full text]
  • Survey of Commercial Outcomes from Public Research (Scopr) 2019 Report
    techtransfer.org.au SURVEY OF COMMERCIAL OUTCOMES FROM PUBLIC RESEARCH (SCOPR) 2019 REPORT Survey and report delivered by FOREWORD There is an ever-present imperative to capture the commercial value of our research endeavour for our future wellbeing. To do so strategically, decision makers from laboratory, institutional and government levels need insights into how the research sector is currently engaging with industry to transfer knowledge and innovation, and thereby deliver benefits to our society from the fruits of our research. For many years in Australia there has been a focus on improving innovation metrics, thus I am delighted to acknowledge the initiative of gemaker and Knowledge Commercialisation Australasia (KCA) in producing the inaugural Survey of Commercial Outcomes from Public Research (SCOPR). The SCOPR takes its lead from the National Survey of Research Commercialisation (NSRC) produced since 2000 by the Department of Industry, Science, Energy and Resources. To avoid duplication, the Department has decided to cease the NSRC and will work with KCA to share knowledge, and access data collected by SCOPR. As we face the COVID-19 pandemic, effective knowledge transfer is more important than ever, so I hope that this report will spur our research institutions to even greater achievements. Realising effective knowledge transfer will depend on having skilled commercialisation professionals who can help researchers turn great ideas into beneficial products and services. I applaud KCA’s support for technology transfer professionals
    [Show full text]
  • Human DECR1 Is an Androgen-Repressed Survival Factor
    RESEARCH ARTICLE Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis Zeyad D Nassar1,2†, Chui Yan Mah1,2†, Jonas Dehairs3, Ingrid JG Burvenich4, Swati Irani1,2, Margaret M Centenera1,2, Madison Helm1,2, Raj K Shrestha5, Max Moldovan2, Anthony S Don6, Jeff Holst7, Andrew M Scott4, Lisa G Horvath8, David J Lynn2,9, Luke A Selth1,5,9, Andrew J Hoy10, Johannes V Swinnen3, Lisa M Butler1,2* 1University of Adelaide Medical School and Freemasons Foundation Centre for Men’s Health, University of Adelaide, Adelaide, Australia; 2South Australian Health and Medical Research Institute, Adelaide, Australia; 3KU Leuven- University of Leuven, LKI- Leuven Cancer Institute, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium; 4Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia; 5Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, Australia; 6NHMRC Clinical Trials Centre, and Centenary Institute, The University of Sydney, Camperdown, Australia; 7Translational Cancer Metabolism Laboratory, School of Medical Sciences and Prince of Wales Clinical School, UNSW Sydney, Sydney, Australia; 8Garvan Institute of Medical Research, NSW 2010; University of Sydney, NSW 2006; and University of New South Wales, Darlinghurst, Australia; 9College of Medicine and Public Health, Flinders University, Bedford Park, Australia; 10Discipline of Physiology, School of *For correspondence: Medical Sciences, Charles Perkins Centre, Faculty of Medicine and Health, The [email protected] University of Sydney, Camperdown, Australia †These authors contributed equally to this work Competing interests: The b authors declare that no Abstract Fatty acid -oxidation (FAO) is the main bioenergetic pathway in human prostate competing interests exist.
    [Show full text]
  • 2.6 Oceania 145 2.6 OCEANIA
    Regional Overview 2.6 Oceania 145 2.6 OCEANIA AUSTRALIA FIJI KIRIBATI MARSHALL ISLANDS MICRONESIA, FEDERATED STATES OF NAURU NEW ZEALAND PALAU PAPUA NEW GUINEA SAMOA SOLOMON ISLANDS TIMOR LESTE TONGA TUVALU VANUATU 146 Global State of Harm Reduction 2020 TABLE 2.6.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Oceania Country/ People who HIV Hepatitis C Hepatitis B Harm reduction response territory with inject drugs prevalence (anti-HCV) (anti-HBsAg) reported among prevalence prevalence injecting drug people who among among 1 Peer use inject drugs people who people who 2 3 4 (%) inject drugs inject drugs NSP OAT distribution DCRs (%) (%) of naloxone (2,940)7 Australia 75,1785[2] 2.3[3] 45[4] 4.0[5] (4,182)6[2] [7,8] 2 (B,M)[6] Federated States nk nk nk nk x x x x of Micronesia Fiji nk nk nk nk x x x x Kiribati nk nk nk nk x x x x Marshall Islands nk nk nk nk x x x x New Zealand 18,0008[10] 0.2[10] 589[10] nk (185)10[11] (B,M)[11,12] 11[9] x Palau nk nk nk nk x x x x Papua New nk nk nk nk x x x x Guinea Samoa nk nk nk nk x x x x Solomon Islands nk nk nk nk x x x x Timor Leste nk nk nk nk x x x x Tonga nk nk nk nk x x x x Vanuatu nk nk nk nk x x x x nk = not known 1 Countries with reported injecting drug use according to Larney et al 2017.
    [Show full text]